Press Releases

The Global Genomic Cancer Panel and Profiling Market is anticipated to grow from USD 9.20 billion in 2023 to USD 25.64 billion by 2030, at a fairly high CAGR of around 8.33% during the forecast period 2025 to 2030.

This growth of the global genomic cancer panel and profiling market is supposed to continue at a high CAGR due to the growing awareness regarding the importance of early cancer detection in patients. 

The growth of the global genomic cancer panel and profiling market is facilitated by the developments in the field of genomic research, the appreciation and growing popularity of liquid biopsy tests, the increasing changes in the lifestyle of people putting them at risk of cancer, and the growing emphasis on precision medicine in the oncology periphery. There has also been a growing need for it in the developed countries due to their aging population. Moreover, such profiling helps doctors to choose the best treatment for a patient which further increases its significance and growth prospects. It helps in developing new treatment processes and facilitates clinical and drug trials and allied research for new drugs. Offering predictive data, it provides insights into cancer type and its aggressiveness, or chances of its recurrence. And, all these are fairly cost-effective. All these factors drive the global genomic cancer panel and profiling market northward.

Browse 86 market data Tables and 50 Figures spread through 192 Pages and in-depth TOC on Global Genomic Cancer Panel and Profiling Market By Tissue Testing Type (Solid and Liquid), By Cancer Panel Type (Single-Gene and Multiple-Gene), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer and Other), By Application (Clinical and Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC) and Others), By End-User (Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes and Other) and by Region (North America, Europe, Asia-Pacific, Latin America and Rest of the World) - Global Forecast to 2030

Global Genomic Cancer Panel And Profiling Market Segmentation and Key Players

By tissue testing, liquid tissue testing dominate the global genomic cancer panel and profiling market.

Based on tissue testing, the global genomic cancer panel and profiling market can be divided into solid and liquid tissue testing. Out of these two segments, the liquid tissue testing segment is supposed to grow at a faster rate since it will become the more common testing method during the forecast period.

“North America is anticipated to register the fastest CAGR during the forecast period, i.e., 2025-2030 in the genomic cancer panel and profiling market.”

Key players of The Global Genomic Cancer Panel And Profiling Market are Agilent Technologies, Inc., Burning Rock DX, Myriad Genetics, ARUP Laboratories, Danaher Corporation (Integrated DNA Technologies, Inc.), Caris Life Sciences, Thermo Fisher Scientific, Inc., Exact Sciences Corporation, Fulgent Genetics, F. Hoffmann-La Roche Ltd., Genecast Biotechnology Co. Ltd., Illumina, Inc., Invitae Corporation.

Recent Developments by Key Players

Recently, Agilent Technologies, launched the Agilent ProteoAnalyzer system to boost capabilities in protein analysis. The Agilent ProteoAnalyzer system is a new automated parallel capillary electrophoresis system for protein analysis that brings more efficiency, versatility and reliability in protein QC workflows by automating the separation, data processing and simplifying sample preparation steps. 

Myriad Genetics in partnership joined hands with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad's minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. 

Global genomic cancer panel and profiling market coverage (By Value)

• By Tissue Testing Type Insight and Forecast 2025-2030
  • Solid
  • Liquid
• By Cancer Panel Type Insight and Forecast 2025-2030
  • Single-gene
  • Multi-gene
• By Cancer Type Insight and Forecast 2025-2030
  • Lung
  • Breast
  • Colon
  • Prostate
  • Other
• By Application Type Insight and Forecast 2025-2030
• • Clinical
  • Research
• By Technology Type Insight and Forecast 2025-2030
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others
• By End-User Type Insight and Forecast 2025-2030
  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutes
  • Others

Geographical Segmentation

Global Genomic Cancer Panel and Profiling Market by Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
• Latin America
  • Brazil
  • Mexico
  • Other Countries
• Rest of the World
  • Saudi Arabia
  • South Africa
  •  U.A.E
  • Other Countries